$CRDF
Cardiff Oncology, Inc. Stock $crdf

$crdf Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000162828023015692 Filed on May 04, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q4
Revenue	$108.0K	$83.00K	$128.0K
YoY Change	18.68%	12.16%	-3.76%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.296M	$3.083M	$3.078M
YoY Change	39.21%	-21.75%	-19.74%
% of Gross Profit
Research & Development	$8.020M	$9.052M	$6.442M
YoY Change	7.68%	25.58%	10.61%
% of Gross Profit
Depreciation & Amortization	$98.00K	$90.00K	$86.00K
YoY Change	157.89%	190.32%	-23.89%
% of Gross Profit
Operating Expenses	$12.32M	$12.14M	$9.520M
YoY Change	16.92%	8.85%	-1.44%
Operating Profit	-$12.21M	-$12.05M
YoY Change	16.9%	8.83%
Interest Expense	$1.053M	$940.0K	$740.0K
YoY Change	316.21%	623.08%	780.95%
% of Operating Profit
Other Income/Expense, Net	$1.058M	$829.0K	-$45.00K
YoY Change		923.46%
Pretax Income	-$11.15M	-$11.22M	-$8.697M
YoY Change	6.77%	2.09%	-7.89%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$11.15M	-$11.22M	-$8.703M
YoY Change	6.77%	2.09%	-7.83%
Net Earnings / Revenue	-10324.07%	-13521.69%	-6799.22%
Basic Earnings Per Share	-$0.25	-$0.25
Diluted Earnings Per Share	-$0.25	-$0.25	-$0.20
COMMON SHARES
Basic Shares Outstanding	44.68M shares	44.68M shares	44.68M shares
Diluted Shares Outstanding	44.68M shares	44.68M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$60.67M	$65.54M	$100.3M
YoY Change	-47.56%	-42.74%	-6.75%
Cash & Equivalents	$19.37M	$15.02M	$16.35M
Short-Term Investments	$41.30M	$50.52M	$83.92M
Other Short-Term Assets	$3.142M	$4.109M	$5.246M
YoY Change	-35.31%	-31.48%	9.96%
Inventory
Prepaid Expenses	$3.142M	$4.109M	$5.246M
Receivables	$161.0K	$676.0K	$771.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$92.73M	$101.8M	$111.3M
YoY Change	-27.22%	-25.07%	-23.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.356M	$1.320M	$1.269M
YoY Change	19.16%	140.0%	232.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.390M	$1.361M	$1.387M
YoY Change	651.35%	623.94%	480.33%
Total Long-Term Assets	$4.724M	$4.796M	$4.907M
YoY Change	22.8%	41.14%	43.61%
TOTAL ASSETS
Total Short-Term Assets	$92.73M	$101.8M	$111.3M
Total Long-Term Assets	$4.724M	$4.796M	$4.907M
Total Assets	$97.46M	$106.5M	$116.2M
YoY Change	-25.75%	-23.46%	-22.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.939M	$2.914M	$1.956M
YoY Change	93.1%	131.09%	35.93%
Accrued Expenses	$5.501M	$4.555M	$5.177M
YoY Change	-12.39%	-3.86%	14.36%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.123M	$8.148M	$7.808M
YoY Change	7.57%	22.27%	19.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.753M	$1.898M	$2.040M
YoY Change	-23.98%	-22.15%
Total Long-Term Liabilities	$1.753M	$1.898M	$2.040M
YoY Change	-23.98%	-22.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.123M	$8.148M	$7.808M
Total Long-Term Liabilities	$1.753M	$1.898M	$2.040M
Total Liabilities	$10.88M	$10.05M	$9.848M
YoY Change	0.83%	10.37%	7.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$320.5M	-$309.3M	-$298.1M
YoY Change	13.94%	14.22%	14.74%
Common Stock	$4.000K	$4.000K	$4.000K
YoY Change	0.0%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$86.58M	$96.50M	$106.3M
YoY Change
Total Liabilities & Shareholders Equity	$97.46M	$106.5M	$116.2M
YoY Change	-25.75%	-23.46%	-22.3%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$11.15M	-$11.22M	-$8.703M
YoY Change	6.77%	2.09%	-7.83%
Depreciation, Depletion And Amortization	$98.00K	$90.00K	$86.00K
YoY Change	157.89%	190.32%	-23.89%
Cash From Operating Activities	-$7.132M	-$8.659M	-$9.390M
YoY Change	6.53%	-15.51%	27.06%
INVESTING ACTIVITIES
Capital Expenditures	$251.0K	$8.000K	$75.00K
YoY Change	-180.45%	-95.32%	-170.09%
Acquisitions
YoY Change
Other Investing Activities	$11.74M	$7.337M	$7.095M
YoY Change	48.17%	-60.4%	-181.67%
Cash From Investing Activities	$11.48M	$7.329M	$7.020M
YoY Change	50.95%	-60.08%	-179.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$0.00	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-7.132M	-$8.659M	-9.390M
Cash From Investing Activities	11.48M	$7.329M	7.020M
Cash From Financing Activities	0.000	$0.00	0.000
Net Change In Cash	4.352M	-$1.330M	-2.370M
YoY Change	376.67%	-116.4%	93.94%
FREE CASH FLOW
Cash From Operating Activities	-$7.132M	-$8.659M	-$9.390M
Capital Expenditures	$251.0K	$8.000K	$75.00K
Free Cash Flow	-$7.383M	-$8.667M	-$9.465M
YoY Change	15.67%	-16.82%	29.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001213037
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-35558
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	CARDIFF ONCOLOGY, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-2004382
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	11055 Flintkote Avenue
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2023Q1	dei	City Area Code CityAreaCode	858
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	952-7570
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock
CY2023Q1	dei	Trading Symbol TradingSymbol	CRDF
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44677169	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15017000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16347000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	81951000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	88920000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	676000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	771000	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4109000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5246000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	101753000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	111284000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1320000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1269000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2115000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2251000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1361000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1387000	usd
CY2023Q1	us-gaap	Assets Assets	106549000	usd
CY2022Q4	us-gaap	Assets Assets	116191000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2914000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1956000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4555000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5177000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	679000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	675000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	8148000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7808000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1898000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2040000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	10046000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	9848000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q1	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	1050000	usd
CY2022Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	1044000	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44677000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44677000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44677000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44677000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	405898000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	404834000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-76000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-395000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-309323000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-298100000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	96503000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	106343000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	106549000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	116191000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	83000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	74000	usd
CY2023Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	9052000	usd
CY2022Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	7208000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3083000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3940000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	12135000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	11148000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12052000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11074000	usd
CY2023Q1	us-gaap	Interest Income Operating InterestIncomeOperating	940000	usd
CY2022Q1	us-gaap	Interest Income Operating InterestIncomeOperating	130000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-111000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-49000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	829000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	81000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11223000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-10993000	usd
CY2023Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6000	usd
CY2022Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11229000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10999000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44677000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44677000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43231000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43231000	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11223000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-10993000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	319000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-606000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10904000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11599000	usd
CY2023Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6000	usd
CY2022Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6000	usd
CY2023Q1	crdf	Comprehensive Income Loss Available To Common Stockholders Basic ComprehensiveIncomeLossAvailableToCommonStockholdersBasic	-10910000	usd
CY2022Q1	crdf	Comprehensive Income Loss Available To Common Stockholders Basic ComprehensiveIncomeLossAvailableToCommonStockholdersBasic	-11605000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	106343000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1064000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	319000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11223000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	96503000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	140417000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1152000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-606000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	-1000	usd
CY2022Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6000	usd
CY2022Q1	crdf	Release Of Clinical Trial Funding Commitment ReleaseOfClinicalTrialFundingCommitment	139000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-10993000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	130102000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11223000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-10993000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	90000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	31000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1064000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1152000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	163000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-346000	usd
CY2023Q1	crdf	Release Of Clinical Trial Funding Commitment For Services Received ReleaseOfClinicalTrialFundingCommitmentForServicesReceived	0	usd
CY2022Q1	crdf	Release Of Clinical Trial Funding Commitment For Services Received ReleaseOfClinicalTrialFundingCommitmentForServicesReceived	139000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-26000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-51000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-95000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-88000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1251000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1141000	usd
CY2023Q1	crdf	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-136000	usd
CY2022Q1	crdf	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-136000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	203000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	0	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-138000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-16000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-42000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8659000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10249000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	171000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	42983000	usd
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	38217000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	37327000	usd
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	36773000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1681000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	17085000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7329000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18358000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1330000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8109000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16347000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11943000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15017000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20052000	usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	133000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	27000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	97000000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	31354000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10694244	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11300897	shares
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	50673000	usd
CY2023Q1	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent	12000	usd
CY2023Q1	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent	165000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	50520000	usd
CY2023Q1	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	104000	usd
CY2023Q1	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	27000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	31431000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	82027000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	116000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	192000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	81951000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	84299000	usd
CY2022Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent	19000	usd
CY2022Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent	394000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	83924000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	5016000	usd
CY2022Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	1000	usd
CY2022Q4	crdf	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	21000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	4996000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	89315000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	20000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	415000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	88920000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4779000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4682000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3459000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3413000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1320000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1269000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	983000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1849000	usd
CY2023Q1	crdf	Accrued Clinical Trial AccruedClinicalTrial	2709000	usd
CY2022Q4	crdf	Accrued Clinical Trial AccruedClinicalTrial	2333000	usd
CY2023Q1	crdf	Accrued Research Agreements AccruedResearchAgreements	571000	usd
CY2022Q4	crdf	Accrued Research Agreements AccruedResearchAgreements	509000	usd
CY2023Q1	crdf	Accrued Director Fees AccruedDirectorFees	125000	usd
CY2022Q4	crdf	Accrued Director Fees AccruedDirectorFees	125000	usd
CY2023Q1	crdf	Patent License And Other Fees Payable PatentLicenseAndOtherFeesPayable	59000	usd
CY2022Q4	crdf	Patent License And Other Fees Payable PatentLicenseAndOtherFeesPayable	24000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	108000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	337000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4555000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5177000	usd
CY2023Q1	crdf	Lessee Operating Lease Monthly Rent Payment LesseeOperatingLeaseMonthlyRentPayment	61000	usd
CY2023Q1	crdf	Lessee Operating Lease Annual Rent Increase Percentage LesseeOperatingLeaseAnnualRentIncreasePercentage	0.03
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	183000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	191000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	183000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	191000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2115000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2251000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	679000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	675000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1898000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2040000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2577000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2715000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M12D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	185000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	70000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	491000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	754000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	775000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	796000	usd
CY2023Q1	crdf	Lessee Operating Lease Liability To Be Paid After Year Three LesseeOperatingLeaseLiabilityToBePaidAfterYearThree	136000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2952000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	375000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2577000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1064000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1152000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1900000	usd
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1000	usd
CY2023Q1	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Expired During Period ClassOfWarrantOrRightWeightedAverageExercisePriceExpiredDuringPeriod	101.52
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	3150000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	5150000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	3150000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4360968	shares
CY2022Q4	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	5.33
CY2022	crdf	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P2Y1M6D
CY2023Q1	crdf	Class Of Warrant Or Right Expired During Period ClassOfWarrantOrRightExpiredDuringPeriod	64496	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4296472	shares
CY2023Q1	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	3.89
CY2023Q1	crdf	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P1Y9M18D
CY2023Q1	crdf	Collaborative Arrangement Rights And Obligations Milestone And Royalty Payments Made CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade	0	usd
CY2022Q1	crdf	Collaborative Arrangement Rights And Obligations Milestone And Royalty Payments Made CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade	0	usd

Files In Submission

Name	View Source	Status
0001628280-23-015692-index-headers.html	Edgar Link	pending
0001628280-23-015692-index.html	Edgar Link	pending
0001628280-23-015692.txt	Edgar Link	pending
0001628280-23-015692-xbrl.zip	Edgar Link	pending
crdf-033123exhibit311.htm	Edgar Link	pending
crdf-033123exhibit312.htm	Edgar Link	pending
crdf-033123exhibit321.htm	Edgar Link	pending
crdf-033123exhibit322.htm	Edgar Link	pending
crdf-20230331.htm	Edgar Link	pending
crdf-20230331.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
crdf-20230331_cal.xml	Edgar Link	unprocessable
crdf-20230331_def.xml	Edgar Link	unprocessable
crdf-20230331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
crdf-20230331_pre.xml	Edgar Link	unprocessable
crdf-20230331_htm.xml	Edgar Link	completed
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRDF
Cardiff Oncology, Inc. Stock $crdf

2023 Q2 Form 10-Q Financial Statement

#000162828023015692 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF Cardiff Oncology, Inc. Stock $crdf

2023 Q2 Form 10-Q Financial Statement

#000162828023015692 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF
Cardiff Oncology, Inc. Stock $crdf